<DOC>
	<DOCNO>NCT00193232</DOCNO>
	<brief_summary>Evaluation effectiveness weekly docetaxel/bortezomib first-line chemotherapy patient advance hormone-refractory prostate cancer .</brief_summary>
	<brief_title>Weekly Docetaxel Bortezomib Treatment Advanced Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Docetaxel + Bortezomib Patients objective response stable disease continue treatment eight course disease progression document .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Prostate cancer , objective evidence metastatic disease Progression receive androgen ablation therapy No previous chemotherapy Measurable evaluable disease conjunction elevate serum PSA level ECOG performance status 0 , 1 , 2 Adequate bone marrow , liver kidney function Voluntarily provide write informed consent You participate study follow apply : Moderate severe peripheral neuropathy Age &lt; 18 year Other serious medical condition may interfere protocol therapy Other active malignancy history treatment invasive cancer within 3 year Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>